XML 42 R15.htm IDEA: XBRL DOCUMENT
v3.22.4

CAPITALIZED FEES PAID | 12 Months Ended
--- | ---
Dec. 31, 2022
Capitalized Contract Cost [Abstract] |
CAPITALIZED FEES PAID | 7. CAPITALIZED FEES PAID Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:
|  |  |  | December 31, |
(In thousands) |  | Amortization period |  | 2022 |  |  | 2021 |
United States |  | 2013-2030 |  | $ | 120,000 |  |  | $ | 120,000 |
Europe |  | 2013-2029 |  |  | 60,000 |  |  |  | 60,000 |
Japan |  | 2013-2029 |  |  | 40,000 |  |  |  | 40,000 |
Gross carrying value |  |  |  |  | 220,000 |  |  |  | 220,000 |
Accumulated amortization |  |  |  |  | (122,393 | ) |  |  | (108,570 | )
Net carrying value |  |  |  | $ | 97,607 |  |  | $ | 111,430 |
These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2022, the weighted average remaining amortization period was 7.1 y ears. Additional information regarding these milestone fees is included in Note 3, “Revenue Recognition”. Amortization for each of the years ended December 31, 2022, 2021 and 2020 was $13.8 million. The remaining estimated amortization is $13.8 million for each of the years from 2023 to 2027 and $28.6 million thereafter.

X
- Definition The entire disclosure for information about capitalized fees paid. + References No definition available. + Details
Name: | inva_CapitalizedFeesPaidDisclosureTextBlock
Namespace Prefix: | inva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CapitalizedContractCostAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration